Phase 1B open-label, multicenter clinical study of the safety and activity of intravenous administration of SNS-595 in patients with advanced hematologic malignancies (SPO- 595-0004).

Trial Profile

Phase 1B open-label, multicenter clinical study of the safety and activity of intravenous administration of SNS-595 in patients with advanced hematologic malignancies (SPO- 595-0004).

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Vosaroxin (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2011 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2011 Results have been published in Leukaemia, according to a Sunesis Pharmaceuticals media release.
    • 17 Mar 2011 NCT report patient number as 30 and trial status as completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top